Since the first case in December 2019, coronavirus disease 2019 (COVID-19) has been responsible for more than 340 million infections and over 5.5 million deaths.1 Though most of the morbidity and mortality associated with COVID-19 is related to pulmonary complications, the disease has had wide-ranging systemic effects, including a range of neurological manifestations2,3 and disruption of coagulation homeostasis.4-7 This disruption in normal coagulation may trigger abnormal clotting events such as venous thromboembolism and stroke.8-10 Cerebral venous thrombosis (CVT) is a rare cause of stroke caused by the formation of clots in the brain’s venous system. The incidence of CVT has been reported to increase over the last decade, either from changing risk factors or improved detection.11-13 Compared to other forms of stroke, the incidence of CVT is more common in younger patients and women. CVT generally has a favorable prognosis with a good 90-day neurological outcome seen in greater than 80% of patients.